Our work is regularly covered by the leading media organisations around the world. This section serves as a repository of all official press releases issued by our Corporate Communications and Investor Relations teams. You can also browse through the selection of media articles on Laurus Labs and relevant reportage.
19 May 2020
Laurus Labs Press Release
30 Apr 2020
Laurus Labs Q4 FY20 Results Press Release April 30 2020
30 Apr 2020
Laurus Labs Press release Q4 Results FY 2020
30 Jan 2020
Laurus Labs Financial Results Q3 FY 2020 Press Release
08 Nov 2019
Laurus Labs completed the USFDA Inspection of its FDF & API Integrated Facility, Unit 2, at Visakhapatnam
30 Oct 2019
Laurus Labs Financial Results Q2 FY 2020 Press Release
18 Sep 2019
Laurus Labs to acquire the Subsidiary Company of Aspen Pharmacare, South Africa
02 Aug 2019
Q1 FY20 Results: Revenues up by 2 percent
22 July 2019
Laurus Labs' exclusive distribution partner Rising Pharmaceuticals, launches Pregabalin Capsules in US market
12 July 2019
Laurus Labs completed the US FDA inspection of Unit 4 at Visakhapatnam
14 June 2019
USFDA inspection of API facilites Unit 1 & 3 at Visakhapatnam
02 May 2019
FY 19 : Laurus Labs revenues up by 11.5 percent in Q4
26 Mar 2019
FY 19 : Laurus Labs enters into strategic partnership agreement with the Global Fund
11 Mar 2019
FY 19 : Laurus Labs receives two approvals from USFDA
3 Feb 2019
FY 19 : Laurus Labs received tentative approval from USFDA under PEPFAR for TLD
FDC
3 Feb 2019
FY 19 : USFDA Approval for TLD Tablets and EIR from USFDA
31 Jan 2019
FY 19 : Laurus Labs Revenue Grew 11% in Q3 FY19
1 Nov 2018
FY 18 : Laurus Labs Financial Results Q2 FY2019 Press Release
23 Oct 2018
FY 18 : Press Release Laurus Labs Oct 23 2018
29 Aug 2018
FY 18 : Press Release 29 Aug 2018 - Metformin USFDA Approval
3 Aug 2018
FY 18 : Press Release of Q1 Results 2018-19
10 May 2018
FY 17 : Press Release of Q4 Results 2017-18
1 March 2018
FY 17 : Intimation of completion of USFDA inspection of unit2 with no observations
29 January 2018
FY 17 : Press Release of Q3 9M Results 2017-18
17 January 2018
FY 17 : LAURUS LABS CERTIFIED AS THE “GREAT PLACE TO WORK” IN THE LARGE SIZED ORGANISATIONCATEGORY IN INDIA
9 November 2017
FY 17 : Q2 H1 Results 2017-18 Press Release
10 November 2017
FY 17 : Analyst and Investor Meet Intimation 10-11-2017
15 September 2017
FY 17 : Unit 2 receives EIR from USFDA and completes German Regulatory Authority inspection;
18 August 2017
FY 17 : Laurus Labs completed the USFDA inspection of its API facilities Unit 1 & 3 at Visakhapatnam
10 August 2017
FY 17 : Press Release of Q1 Results 2017-18
5 July 2017
FY 17 : Laurus Labs Credit Rating Improved
18 May 2017
FY 17 : Laurus Labs PAT grows by 40%
9 February 2017
FY 17 : Laurus Labs demonstrates strong Q3 growth In the first quarterly results after successful IPO
26 Feb 2020
Laurus Labs banking on vertical integration to crack anti-HIV tenders and US formulations mkts
31 Jan 2020
Laurus Labs Standalone December 2019 Net Sales at Rs 720.99 crore, up 40.61% Y-o-Y
30 Jan 2020
Laurus Labs Q3 net profit rises 4-fold at Rs 73 crore
30 Jan 2020
Laurus Labs net trebles at Rs. 73.5 crore
28 Dec 2019
Laurus Labs eyes bigger play in generic formulations segment
11 Nov 2019
Laurus Labs shares up on USFDA observations on Visakhapatnam unit
01 Nov 2019
Laurus Labs consolidated net profit rises 248.86% in the September 2019 quarter
01 Nov 2019
Laurus Labs Standalone September 2019 Net Sales at Rs 705.86 crore, up 22.84% Y-o-Y
31 Oct 2019
Laurus Labs Ltd crosses revenue of Rs. 700 crores in Q2 FY20
23 Oct 2019
CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited
18 Sep 2019
Laurus Labs to acquire South Africa's Aspen Pharmacare subsidiary
18 Sep 2019
Warburg Pincus-backed Laurus Labs buys South African firm
05 Sep 2019
Laurus Labs gets approval from the FDA
29 Aug 2019
Laurus Labs gets USFDA approval for Metformin tablets
05 Aug 2019
Laurus Labs Ltd CEO Satyanarayana Chava speaks on Q1 results
22 Jul 2019
Laurus Labs partner Rising Pharma launches neuropathic pain capsules in US
12 Jul 2019
Laurus Labs gets USFDA nod for Unit-4
12 Jul 2019
Laurus Labs Vizag unit completes USFDA inspection
15 Jun 2019
Laurus Labs gets 2 USFDA observations for its API facilities in Visakhapatnam
27 March 2019
Laurus Labs joins hand with Global Fund to supply drugs
26 March 2019
Laurus Labs seals deal with Global Fund to supply ARV combination medicine
26 March 2019
Laurus Labs jumps 4% on strategic partnership with Global Fund
26 March 2019
Larus Labs enters agreement with Global Fund for supply of AIDS drugs
26 March 2019
Laurus Labs firms up after partnership with Global Fund
26 March 2019
Laurus Labs in pact with The Global Fund
26 March 2019
Laurus Labs enters into strategic partnership agreement with Global Fund
14 February 2019
Laurus Labs invests over $100 million on formulation biz
3 February 2019
Laurus Labs gets USFDA approval for HIV drug
3 February 2019
Laurus Labs gets USFDA nod for HIV drug
2 December 2018
Laurus Labs-Aspen Pharmacare launch HIV drug in South Africa
3 November 2018
Laurus Labs Vizag API unit gets 1 USFDA observation
2 November 2018
Laurus Labs Vizag API unit gets 1 USFDA observation
23 October 2018
Laurus Labs to expand its footprint in US, China
30 August 2018
Laurus Labs gets USFDA nod for diabetes drug
30 August 2018
Laurus Labs rises nearly 6% post USFDA approval for diabetes drug
29 August 2018
Laurus Labs gets USFDA nod for diabetes drug
29 August 2018
Laurus Labs gets USFDA nod for diabetes drug
11 August 2017
Expect to get 2 ANDA approvals in FY18: Laurus Labs
11 August 2017
LAURAS LABS Q1: PROFIT JUMPS 51%
22 May 2017
Laurus Labs Q4 net rises 39%
19 May 2017
Laurus Labs says API facility of Unit 2 completed successful USFDA inspection
19 May 2017
Laurus Labs Vizag unit clears USFDA inspection ahead of debut in US generics market
Laurus Labs standalone net profit rises 39.11% in the March 2017 quarter
31 March 2017
Laurus Labs' PAT increases by 39% to Rs 74.3-cr.
18 May 2017
Laurus Labs posts Rs 74 crore net profit in Q4
27 March 2017
Citi bullish on Laurus; return ratios will improve post formulations: Satyanarayana Chava, Founder & CEO
Laurus Labs December quarter net up 17.5% to Rs 47 crore
10 February 2017
Laurus Labs hopes better profits in Q4 with lower interest outgo after debt retirement
10 February 2017
Laurus Labs December quarter net up 17.5% to Rs 47 crore
10 February 2017
Laurus Labs Q3 net up 18%
Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO
9 February 2017
Laurus Labs net profit up 17.5% to Rs 47.2 crore in Q3
9 February 2017
Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO
10 February 2017
Laurus Labs December quarter net up 17.5% to Rs 47 crore
Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO
11 February 2017
Laurus Labs December quarter net up 17.5% to Rs 47 crore
13 February 2017
Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO
9 February 2017
Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO
Laurus Labs Demonstrates Strong Q3 Growth In The First Quarterly Results After Successful IPO
Laurus Generics GmbH 
Laurus Synthesis 
